Pagibaximab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | staphylococcal lipoteichoic acid |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
Chemical and physical data | |
Formula | C6462H9996N1728O2028S54 |
Molar mass | 072.36 g·mol−1 146 |
![]() ![]() |
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010[update], it is undergoing Phase II/III clinical trials.[1][2]
References[edit]
- ^ Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial Agents and Chemotherapy. 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668. PMID 19380597.
- ^ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov
![]() | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |